# S0916, MLN1202 in Treating Patients With Bone Metastases

> **NCT01015560** · PHASE2 · COMPLETED · sponsor: **SWOG Cancer Research Network** · enrollment: 44 (actual)

## Conditions studied

- Metastatic Cancer
- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** anti-CCR2 monoclonal antibody MLN1202
- **GENETIC:** polymorphism analysis
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT01015560
- **Lead sponsor:** SWOG Cancer Research Network
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2018-08-09

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01015560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01015560, "S0916, MLN1202 in Treating Patients With Bone Metastases". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01015560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*